Potential new option for Alzheimer's patients
October 8, 2012 (WLS) -- Two large studies show patients with mild Alzheimer's disease taking an experimental drug had 34 percent less decline in memory over 18 months compared with those taking placebos.
The drug is called solanezumab. The analysis of data from two large studies were presented Monday at a medical meeting in Boston. But this closely watched drug did not significantly protect against loss of physical functions.
Scientists say the latest data lend further credence to the theory that Alzheimer's must be attacked early in the disease for drugs to have a clinically meaningful impact.
The drug works by blocking a protein called beta amyloid that forms plaque deposits on the brain.
- Carbon monoxide hospitalizes 12 in Skokie
- Chicago radio legend Larry Lujack dies at 73 1 min ago
- Video: I-Team Mall Security
- ABC7 Weather Forecast
- CTA Blue Line train service resumes
- 3 dead in 3 South Side shootings in 3 hours
- Deal requires removal of Chicago 'petcoke' piles
- Rogers Park stabbing seriously injures woman, 21
- Target: 40M card accounts may be breached
- City triples budget to board up closed CPS schools
- Ga lottery winner to get Mega Millions $120M lump sum
- Derrick Rose No. 3 in NBA Jersey sales 21 min ago
- abcnews: 'Duck Dynasty' Puts Star on Hiatus
- 7 in :77
- Chicago radio legend Larry Lujack dies at 73
1 min ago